» Articles » PMID: 12114426

The Expression of Carbonic Anhydrase II in Hematological Malignancies

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2002 Jul 13
PMID 12114426
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Carbonic anhydrases (CAs) are key enzymes that regulate acid-base homeostasis in both normal and pathological conditions. Recent studies have shown that they are functionally involved in the growth and invasion of cancer cells. However, there are only a few publications on CAs in hematological malignancies.

Experimental Design: Here we investigated the presence of CA isozymes in six malignant hematopoietic cell lines and malignant blast cells of bone marrow samples collected from patients with acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelomonocytic leukemia.

Results: Because three of the malignant hematopoietic cell lines expressed CA II, we also set out to examine its expression in a series of bone marrow samples. Positive reactions were found in 16 of 26 cases (62%) of acute myeloid leukemia, 11 of 15 cases (73%) of acute lymphoblastic leukemia, and 1 of 2 cases (50%) of chronic myelomonocytic leukemia.

Conclusions: The results indicate that CA II expression is not restricted to only one cell lineage but may result from a genetic aberration that occurs in both myeloid and lymphatic lineages or in their progenitor cell. Because CA II is expressed in most patients with leukemic blast cells, CA inhibitors may prove to be of value as an adjunct to chemotherapy for such cancers.

Citing Articles

Design, synthesis, and biological investigation of selective human carbonic anhydrase II, IX, and XII inhibitors using 7-aryl/heteroaryl triazolopyrimidines bearing a sulfanilamide scaffold.

Romagnoli R, De Ventura T, Manfredini S, Baldini E, Supuran C, Nocentini A J Enzyme Inhib Med Chem. 2023; 38(1):2270180.

PMID: 37850364 PMC: 10586084. DOI: 10.1080/14756366.2023.2270180.


Gene expression of carbonic anhydrase 9 (CA9) in acute leukemia as a predictive marker for prognosis.

Alyaqubi K, Dosh R, Al-Fatlawi R, Al-Rehemi S, Hadi N J Med Life. 2022; 15(9):1158-1163.

PMID: 36415514 PMC: 9635246. DOI: 10.25122/jml-2021-0212.


Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.

Chen F, Licarete E, Wu X, Petrusca D, Maguire C, Jacobsen M J Cell Mol Med. 2021; 25(24):11039-11052.

PMID: 34791807 PMC: 8650039. DOI: 10.1111/jcmm.17027.


Targeting the pH Paradigm at the Bedside: A Practical Approach.

Koltai T Int J Mol Sci. 2020; 21(23).

PMID: 33287221 PMC: 7730959. DOI: 10.3390/ijms21239221.


New Monoclonal Antibodies for a Selective Detection of Membrane-Associated and Soluble Forms of Carbonic Anhydrase IX in Human Cell Lines and Biological Samples.

Stravinskiene D, Imbrasaite A, Petrikaite V, Matulis D, Matuliene J, Zvirbliene A Biomolecules. 2019; 9(8).

PMID: 31349673 PMC: 6723738. DOI: 10.3390/biom9080304.